Elevated plasma and vitreous levels of leucine-rich-α2-glycoprotein (LRG1) is associated with the progression of diabetic retinopathy

Session Details

Session Title: Free Paper Session 15: Mixed Session

Session Date/Time: Friday 08/09/2017 | 16:30-18:00

Paper Time: 17:24

Venue: Room 117

First Author: : C.Chen CHINA

Co Author(s): :    X. Chen   K. Liu                          

Abstract Details

Purpose:

Diabetic retinopathy (DR), characterized by retinal microangiopathy, is the leading cause of blindness in the working-age population. This study aimed to investigate the association of plasma and vitreous leucine-rich-α2-glycoprotein (LRG1) with the progression of DR.

Setting:

Shanghai General Hospital, Shanghai Jiao Tong University

Methods:

Cross-sectional study. Apart fromthecontrols, based on international clinical DR severity scales, patients with type 2 diabetes mellitus (T2DM) were classified asT2DM without DR, non-proliferative DR (NPDR), and PDR by two independent ophthalmologists. Plasma samples were obtained from outpatients. Vitreous samples were obtained from inpatients that underwent pars plana vitrectomy. Plasma and vitreous LRG1 were measured by immunoassay. The diagnostic value of plasma LRG1 was tested using receiver operating characteristic (ROC) curves.

Results:

A total of 86 outpatients and 33 inpatients were recruited. ELISA quantificationof LRG1 in plasma showed significant increases in PDR patients (n=22) compared with controls (n=22), T2DM without DR(n=22), and NPDR patients(n=20) (P< .0001). No significant differences were found among controls, T2DM without DR, and NPDR groups. As for the vitreous samples, LRG1 showed significant increases in PDR patients (n=22) compared with controls (n=11, P= .000). The area under the ROC curve value for plasma LRG1 was 0.786 (P<.0001). And the maximal Youden index was 0.4372 and occurred at a LRG1 cut-off of 7357.043pg/mL, with 81.82% sensitivity at 61.90% specificity.

Conclusions:

Elevation of plasma LRG1 may have predictive value for PDR and may afford potential clinical benefit as biomarkers for PDR screening. Its potential as future therapeutic targets and the pathobiological basis need further exploration.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy